<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardiovascular toxicities of molecularly targeted antiangiogenic agents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardiovascular toxicities of molecularly targeted antiangiogenic agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardiovascular toxicities of molecularly targeted antiangiogenic agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Toni K Choueiri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Guru P Sonpavde, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H112181231"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antiangiogenic agents (systemic medications that inhibit angiogenesis) are used in cancer therapy because angiogenesis is required for tumor growth [<a href="#rid1">1</a>]. </p><p>Several classes of antiangiogenic agents are available that block the vascular endothelial growth factor (VEGF) pathway  (<a class="graphic graphic_figure graphicRef76708" href="/z/d/graphic/76708.html" rel="external">figure 1</a>), including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ligand inhibitors</strong> – These bind to and inhibit ligand binding to the VEGF receptor, thereby preventing activation of the receptor. Examples include <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a>, and <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Receptor tyrosine kinase inhibitors (TKIs)</strong> – These block the enzymatic activity of the intracellular domain of the VEGF receptor (VEGFR). Examples include <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">ponatinib</a>, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">tivozanib</a>, and <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a>.</p><p></p><p>Antiangiogenic agents are associated with a wide spectrum of toxicities, which may be fatal in rare cases [<a href="#rid2">2,3</a>]. While some adverse effects are shared with chemotherapy, many are unique to antiangiogenic agents. Toxicities of antiangiogenic agents may be specific to the drug class or to the agent itself. </p><p>This topic will discuss the cardiovascular toxicities of antiangiogenic agents. </p><p>Separate topics discuss:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-cardiovascular toxicities of antiangiogenic agents</strong> – (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/z/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney toxicities of antiangiogenic agents</strong> – (See  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Antiangiogenic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infusion reactions to monoclonal antibodies</strong> – (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The basic science of angiogenesis inhibitors</strong> – (See  <a class="medical medical_review" href="/z/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors"</a>.)</p><p></p><p class="headingAnchor" id="H3265172203"><span class="h1">PATHOPHYSIOLOGY OF CARDIOVASCULAR TOXICITIES</span><span class="headingEndMark"> — </span>The cardiovascular toxicities of angiogenesis agents appear to be generated by negative effects on multiple levels, including myocardial cells, endothelial cells, and pericytes [<a href="#rid4">4</a>]. Thus, the pathophysiology of the cardiovascular toxicities of vascular endothelial growth factor (VEGF) inhibitors is multifactorial and impacted by preexisting comorbidities that reduce vascular reserve [<a href="#rid5">5</a>].</p><p>Many of the data are derived from animal models:</p><p class="bulletIndent1"><span class="glyph">●</span>In animal models, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> increases the vasoconstriction mediated by endothelins, resulting in hypertension and increased cardiac afterload [<a href="#rid6">6</a>]. Reduced myocardial perfusion from this and other VEGF inhibitors can reduce myocardial contractility and lead to both ischemia and heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In animal models, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> induces myocyte necrosis, with surviving myocytes undergoing hypertrophy [<a href="#rid7">7</a>]. Moreover, inhibition of KIT positive stem cells by sorafenib exacerbates damage by decreasing cardiac repair.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">Sunitinib</a> can potentially compromise myocardial energy metabolism by enhancing glycolysis and reducing oxidative phosphorylation [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Animal models have demonstrated acceleration of atherosclerosis from a VEGF receptor inhibitor, potentially explained by disruption of endothelial cell homeostasis by a dose-dependent increase in mitochondrial superoxide generation, resulting in reduced nitric oxide availability and decreased proliferation [<a href="#rid9">9</a>]. The disruption of VEGF-dependent events may lead to downstream endothelial cell apoptosis, plaque erosions, and acute arterial thrombotic events [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A preclinical study described sunitinib-induced pericyte depletion and coronary microvascular dysfunction mediated by targeting the platelet-derived growth factor receptor (PDGFR) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, systemic capillary rarefaction has been observed, which may increase afterload [<a href="#rid12">12</a>]. The afterload increase, coupled with reduced cardiac contractility and myocyte hypertrophy, leads to increased oxygen demand and upregulates the VEGF axis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As anticipated, preexisting coronary artery disease and hypertension have been identified as predictors for the development of heart failure with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other indirect mechanisms that may contribute to cardiovascular toxicities include hypothyroidism resulting from VEGF receptor inhibitors, which may reduce cardiac contractility and preload. Moreover, concurrent or recent use of cardiotoxic chemotherapeutic agents may exacerbate the cardiovascular toxicities of angiogenesis inhibitors.</p><p></p><p class="headingAnchor" id="H89432458"><span class="h1">RISK OF FATALITY</span><span class="headingEndMark"> — </span>Meta-analyses have demonstrated a small risk of fatal adverse events (approximately 1.5 to 2.5 percent, relative risk [RR] 1.5 to 2.2) with both antiangiogenic tyrosine kinase inhibitors (TKIs) and <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> [<a href="#rid2">2,3,15</a>]. In one analysis, bevacizumab was associated with an increased risk of fatal events when used in combination with taxanes or platinum agents (RR 3.49) but not in combination with other agents (RR 0.85) [<a href="#rid2">2</a>].</p><p>In two meta-analyses, hemorrhage was the most common fatal adverse event with both classes of agents; other causes of treatment-related death were cardiac, gastrointestinal tract perforation, hepatic dysfunction, infection, and cerebrovascular events [<a href="#rid2">2,3</a>]. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bleeding'</a>.)</p><p>In another meta-analysis examining fatal events with antiangiogenic TKIs, fatalities from heart failure, pulmonary emboli, hepatic failure, intestinal perforation, and pneumonia/respiratory failure were numerically higher on the TKI treatment arms [<a href="#rid15">15</a>]. In this study, the increased RR for death with the TKIs was statistically significant for patients with renal cell carcinoma (RCC), but not for those with lung cancer. However, the increased risk seen in patients treated for RCC may be ascribed partly to increased exposure time to the antiangiogenic TKI in patients with RCC relative to those with lung cancer.</p><p class="headingAnchor" id="H291525424"><span class="h1">CLASS SIDE EFFECTS OF ALL VEGF INHIBITORS</span></p><p class="headingAnchor" id="H21639449"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Hypertension is a class side effect that is associated with all antiangiogenic agents. Vascular endothelial growth factor (VEGF) plays a key role in the maintenance of vascular homeostasis via mediation of the production of the vasodilator nitric oxide, and decreased vascular resistance through the generation of new blood vessels [<a href="#rid16">16-20</a>]. Both of these influences are associated with decreases in blood pressure. Thus, it is not surprising that inhibition of VEGF signaling might be associated with hypertension [<a href="#rid21">21,22</a>]. Because of this, all trials evaluating inhibitors of angiogenesis have restricted eligibility to patients with controlled blood pressure at baseline.</p><p class="headingAnchor" id="H21639456"><span class="h3">Incidence and characteristics</span><span class="headingEndMark"> — </span>The following key studies have addressed the incidence of hypertension in patients treated with angiogenesis inhibitors:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and meta-analysis including 77 phase III trials, angiogenesis inhibitors were associated with a higher risk of hypertension (odds ratio [OR] 5.28, 95% CI 4.53-6.15) and severe hypertension (OR 5.59, 95% CI 4.67-6.69) [<a href="#rid23">23</a>]. The subgroup analyses examining VEGF ligand inhibitors versus small molecule agents showed no significant differences.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 29,252 patients from 71 randomized controlled trials, hypertension (relative risk [RR] 3.78, 95% CI 3.15-4.54) was reported with VEGF tyrosine kinase inhibitors (TKIs) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 72 randomized controlled trials including 30,013 patients, the incidence of high-grade and all-grade hypertensive events with VEGF receptor (VEGFR) TKIs was 23.0 percent (95% CI 20.1-26.0 percent) and 4.4 percent (95% CI 3.7-5.0 percent), respectively [<a href="#rid25">25</a>]. VEGFR TKIs increased the risk of developing high-grade (RR 4.60, 95% CI 3.92-5.40) and all-grade (RR 3.85, 95% CI 3.37-4.40) hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 12,949 patients treated with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> for advanced solid tumors, the RR of developing "significantly raised" blood pressure (defined as more than one drug needed for treatment, more intensive treatment needed than used previously, or life-threatening consequences such as hypertensive crisis; or grade 3 or 4 hypertension according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events CTCAE  (<a class="graphic graphic_table graphicRef87347" href="/z/d/graphic/87347.html" rel="external">table 1</a>)) among patients receiving bevacizumab was 5.38 (95% CI 3.63-7.97) [<a href="#rid26">26</a>]. Among patients receiving bevacizumab, the overall incidence of all raised blood pressure events was 24 percent (95% CI 20-29 percent), while the incidence of significantly raised blood pressure was 8 percent (95% CI 6-10 percent). Risk was dose dependent; the RRs of severe hypertension at doses of 5 and 2.5 mg/kg per week were 7.17 (95% CI 3.91-13.13) and 4.11 (95% CI 2.49-6.78), respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2017 meta-analysis of individual patient safety data from six randomized placebo-controlled trials, rates of severe hypertension with <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a> were 9 percent, versus 2.5 percent for placebo [<a href="#rid27">27</a>]. For all grades of hypertension, the risk was 21 versus 9 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another meta-analysis analyzed the incidence of hypertension in 13 prospective studies with 4999 patients who were treated with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> for renal cell carcinoma (RCC) or other malignancies [<a href="#rid28">28</a>]. Among patients receiving sunitinib, the overall incidence of all-grade hypertension was 22 percent, with severe hypertension in 7 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Almost identical findings were noted in a systematic review that analyzed the incidence of hypertension in 4599 patients treated with <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> in nine prospective studies [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the VEGFR TKIs, it is unclear if any one agent causes hypertension with greater frequency; in one meta-analysis, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> was associated with higher rates of all-grade hypertension than <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (36 versus 23 and 22 percent, respectively), but similar rates of severe hypertension (6.5 versus 5.7 and 6.8 percent, respectively) [<a href="#rid30">30</a>]. In phase III trials directly comparing TKIs in advanced RCC, pazopanib and sunitinib were associated with similar rates of all-grade hypertension (46 percent, 41 percent), and <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> was associated with somewhat more hypertension compared with sorafenib (40 versus 29 percent) [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent1">On the other hand, higher rates of both all grade (68 percent) and severe (42 percent) hypertension are reported with <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of severe hypertension may be higher with <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> than with other VEGF-targeted therapies, but no direct comparisons of aflibercept with other VEGF inhibitors exist (19.1 percent for aflibercept compared with 1.5 percent for placebo when both were administered in combination with chemotherapy in patients with colorectal cancer [<a href="#rid34">34</a>]).</p><p></p><p>Preexisting hypertension, age ≥60 years, and body mass index (BMI) ≥25 kg/m<sup>2</sup> have been independently associated with a higher risk for anti-VEGF therapy-induced blood pressure elevation [<a href="#rid35">35</a>]. Dramatic increases in both diastolic (up to 27 mmHg [<a href="#rid36">36</a>]) and systolic (up to 29 mmHg [<a href="#rid36">36</a>]) blood pressure may be seen as early as the first week of therapy [<a href="#rid36">36,37</a>]. It is not possible to predict which patients will have this magnitude of blood pressure elevation [<a href="#rid38">38</a>]. There is some evidence that genetic predisposition may play a role, but no reliable markers are available to predict risk that can be used in clinical practice [<a href="#rid39">39,40</a>].</p><p>Because serious adverse events have been associated with unmanaged hypertension, all patients receiving therapy with an angiogenesis inhibitor should have their blood pressure actively monitored during treatment, with more frequent measurement in the first several weeks of therapy. (See <a class="local">'Monitoring and management'</a> below.)</p><p class="headingAnchor" id="H30695629"><span class="h3">Association with antitumor efficacy</span><span class="headingEndMark"> — </span>Several reports note an association between improved antitumor efficacy and the development of systolic or diastolic hypertension during therapy with both <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and the antiangiogenic TKIs [<a href="#rid41">41-49</a>]; however, this has not been seen in all studies [<a href="#rid50">50-52</a>]. The following represents the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a combined series analyzing 544 patients enrolled on four prospective trials of <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> for advanced RCC, antitumor efficacy was significantly better in patients with one or more systolic blood pressure readings ≥140 mmHg (median overall survival, median progression-free survival, and objective response rates were 30.9 versus 7.2 months, 12.5 versus 2.5 months, and 55 versus 9 percent, respectively) [<a href="#rid47">47</a>]. Similar results were seen using a criterion of diastolic blood pressure ≥90 mmHg. Multivariate analysis confirmed that treatment with sunitinib was an independent factor for survival after incorporating other known risk factors (hazard ratio [HR] 0.28, 95% CI 0.22-0.37). Secondary analyses found that the improvement in efficacy was maintained in patients who were treated for hypertension or had a dose reduction of sunitinib [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, a lack of association between early hypertension and clinical benefit from <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> was suggested in an analysis of seven randomized trials of bevacizumab versus no bevacizumab in patients with RCC, colorectal, breast, non-small cell lung, and pancreatic cancer [<a href="#rid51">51</a>]. In six of the seven studies, early hypertension (defined as an increase in systolic blood pressure of &gt;20 mmHg or of diastolic blood pressure &gt;10 mmHg within the first 60 days of treatment) was not predictive of clinical benefit from bevacizumab.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other data suggest that the apparent relationship between efficacy and toxicity may be related to increased drug exposure. In a report that systematically analyzed pharmacokinetic and pharmacodynamic data from six clinical studies of <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, sunitinib dose intensity and cumulative weekly dose correlated with both improved clinical outcomes and maximum blood pressure [<a href="#rid54">54</a>].</p><p></p><p>Hence, further studies are warranted to validate hypertension as a predictive biomarker of efficacy in patients treated with angiogenesis inhibitors.</p><p class="headingAnchor" id="H21639463"><span class="h3">Monitoring and management</span><span class="headingEndMark"> — </span>Although minimalist approaches to managing hypertension for patients with incurable diseases might be favored in some circumstances, management of comorbidities, including hypertension, may actually improve survival [<a href="#rid55">55</a>]. Furthermore, active control of hypertension should allow patients to tolerate the highest effective doses of therapy, for the longest period of time [<a href="#rid38">38</a>].</p><p>The Investigational Drug Steering Committee of the NCI formed a Cardiovascular Toxicities Panel, joining members of its Angiogenesis Task Force with experts in the management of hypertension in cancer patients to generate consensus recommendations for risk assessment, monitoring, and safe administration of angiogenesis inhibitors [<a href="#rid38">38</a>]. Their recommendations included the following four components  (<a class="graphic graphic_table graphicRef73373 graphicRef63338" href="/z/d/graphic/73373.html" rel="external">table 2A-B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Perform a pretreatment evaluation and screening, including formal risk assessment for potential cardiovascular complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify and treat preexisting hypertension before using these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Actively monitor blood pressure during treatment, with more frequent measurement in the first several weeks of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manage blood pressure during therapy, with an ideal goal, when possible, of keeping blood pressure less than 130/80 mmHg for most patients, lower in those with specific preexisting cardiovascular risk factors, such as diabetes or chronic kidney disease. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p>Continuous ambulatory blood pressure monitoring has been proposed for monitoring of blood pressure and management of hypertension in patients with advanced RCC receiving <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid56">56</a>]. However, this approach is not in widespread use, at least in the United States.</p><p>Patients who develop hypertension during treatment (defined as blood pressure ≥140/90 mmHg or a 20 mm increase in diastolic blood pressure over baseline) should be treated with antihypertensives. The choice of agent must take into consideration the severity of the hypertension and the urgency of blood pressure control. (See  <a class="medical medical_review" href="/z/d/html/3830.html" rel="external">"Management of severe asymptomatic hypertension (hypertensive urgencies) in adults"</a>.)</p><p>In addition, several other considerations may influence the choice of antihypertensive therapy. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Optimal anti-hypertensive agents in this context have not been defined. However, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> undergo partial metabolism via cytochrome P450, a system inhibited by some antihypertensive agents (eg, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>) [<a href="#rid21">21</a>]. Therefore, these agents should probably be avoided in patients who develop hypertension while receiving sorafenib or sunitinib.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organ dysfunction and/or adverse effects on organ function may influence the choice and dose of the antihypertensive agent [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with renal cell cancer who develop hypertension while receiving treatment with an antiangiogenic agent, treatment with angiotensin system inhibitors (ASIs; eg, angiotensin converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs]) may be preferred over other agents. (See  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Toxicities of VEGF inhibition (hypertension)'</a>.)</p><p></p><p class="headingAnchor" id="H291526412"><span class="h2">Arterial and venous thromboembolism</span><span class="headingEndMark"> — </span>An increased risk for arterial thromboembolic events (ATEs) has been linked to the use of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>, and a number of the antiangiogenic TKIs [<a href="#rid34">34,58</a>]. As an example, in a systematic review and meta-analysis including 77 phase III trials, angiogenesis inhibitors were associated with a higher risk of arterial thromboembolism (OR 1.52, 95% CI 1.17-1.98), but subgroup analyses did not reveal differences between VEGF ligand inhibitors (antibodies or decoy receptors) and small molecule agents [<a href="#rid23">23</a>].</p><p>On the other hand, whether the risk of venous thromboembolic events (VTEs) is increased in these patients is uncertain; the data are mixed. Notably, patients with prior cardiovascular or venous thrombotic events within 6 to 12 months were not enrolled on clinical trials of these agents in a variety of malignancy types.</p><p class="headingAnchor" id="H292260181"><span class="h3">Pathophysiology</span><span class="headingEndMark"> — </span>The pathophysiology underlying the increased risk of thromboembolism in patients treated with inhibitors of angiogenesis remains unresolved [<a href="#rid59">59</a>]. The main hypothesis is that perturbation of tumor-associated endothelial cells can switch the endothelium from a naturally anticoagulant surface to a prothrombotic surface, thus mediating the activation of systemic coagulation in cancer patients, who are already more susceptible to thromboembolism due to their underlying disease. (See  <a class="medical medical_review" href="/z/d/html/1353.html" rel="external">"Cancer-associated hypercoagulable state: Causes and mechanisms"</a>.)</p><p>The VEGF pathway has been reported to protect and regulate endothelial cell function via pathways that inhibit apoptosis and inflammation. VEGF-induced nitric oxide production by endothelial cells is associated with several vascular protective effects, including inhibition of proliferation of vascular smooth muscle cells, antiplatelet actions, and inhibition of leucocyte adhesion [<a href="#rid60">60,61</a>]. As a consequence, endothelial cell dysfunction may expose pro-thrombotic phospholipids and underlying stroma [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H291526420"><span class="h3">Bevacizumab and aflibercept</span></p><p class="headingAnchor" id="H291526440"><span class="h4">Arterial thromboembolic events</span></p><p class="headingAnchor" id="H3254378052"><span class="h5">Incidence</span><span class="headingEndMark"> — </span>An increased incidence of potentially fatal ATEs (including transient ischemic attacks, strokes, angina, and myocardial infarction) was initially reported with the use of a bevacizumab-containing chemotherapy regimen for advanced colorectal cancer [<a href="#rid63">63</a>]. In randomized trials, the 4 to 5 percent incidence of serious ATEs in patients receiving <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in combination with a short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU)-based chemotherapy regimen represented an approximately two- to threefold higher incidence than in the control groups receiving the same chemotherapy regimen without bevacizumab [<a href="#rid64">64</a>].</p><p>The risk of ATEs in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus chemotherapy compared with chemotherapy alone in a variety of malignancies has been further clarified by the findings from at least four meta-analyses:</p><p class="bulletIndent1"><span class="glyph">●</span>In an individual patient level meta-analysis of data from five trials in three different tumor entities, the use of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> with concomitant chemotherapy increased the risk of an ATE twofold (RR 2.0, 95% CI 1.05-3.75) compared with chemotherapy without bevacizumab [<a href="#rid65">65</a>]. Patients over 65 years of age (hazard ratio [HR] 2.1) and those with a prior history of ATEs (HR 4.18) appeared to be at highest risk for an ATE, particularly if they had both risk factors combined (HR 7.6).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk may also vary according to the type of malignancy. In a trial-level meta-analyses of over 13,000 patients treated on 20 randomized trials, the RR increase for ATEs in patients receiving <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> for a variety of advanced malignancies was 1.46 (95% CI 1.11-1.93); this translated into an incidence of 2.6 percent (95% CI 2-3.5) [<a href="#rid66">66</a>]. The highest ATE incidence was seen in patients treated for mCRC (3.2 percent, 95% CI 1.9-5.4), and the lowest was in patients treated for breast cancer (0.7, 95% CI 0.1-3.6), a diagnosis for which bevacizumab is no longer approved. Incidence rates for patients treated for non-small cell lung cancer (NSCLC) and RCC were 2.5 percent (95% CI 1.8-3.7) and 2.3 percent (95% CI 1.4-3.7), respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A dose-response effect has been shown in only one [<a href="#rid67">67</a>] of three trial-level meta-analyses [<a href="#rid66">66-68</a>].</p><p></p><p>Fewer data are available for <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>. ATEs were not observed in phase I and II trials [<a href="#rid69">69,70</a>]. In a phase III trial of chemotherapy with and without aflibercept in patients with mCRC, the rate of all-grade ATEs in the aflibercept group was 2.6 versus 1.5 percent with chemotherapy alone, but the rate of a grade 3 or 4 event was 1.8 versus 0.5 percent [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H78097915"><span class="h5">Management</span><span class="headingEndMark"> — </span>We do not consider that a prior history of an ATE represents an absolute contraindication to use of antiangiogenic agents. We suggest caution and maintaining a low index of suspicion for drug-related ATEs in patients with a prior history of thromboembolic events. A discussion of the use of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in older adult patients who have a history of an ATE within the past 6 to 12 months can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">"Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status", section on 'Bevacizumab and biosimilars'</a>.)</p><p>The United States Prescribing Information indicates that <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> should be discontinued for any severe ATE, but do not define "severe" [<a href="#rid71">71</a>]. The labeling information for <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> recommends discontinuation of the drug in patients who experience an ATE [<a href="#rid72">72</a>]. We discontinue both drugs for all grade 3 or higher  (<a class="graphic graphic_table graphicRef117315" href="/z/d/graphic/117315.html" rel="external">table 3</a>) new or worsened arterial thrombotic events during therapy, unless the clinical benefits considerably outweigh the risks [<a href="#rid73">73</a>]. Continuation with concurrent anticoagulation might be considered in selected patients who are clearly benefiting from antiangiogenic therapy and who are willing to accept the hypothetical risk from continued use of bevacizumab in this setting.</p><p class="headingAnchor" id="H291526448"><span class="h4">Venous thromboembolism</span></p><p class="headingAnchor" id="H1870717429"><span class="h5">Incidence</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> has been inconsistently associated with an increased risk of VTEs in cancer patients [<a href="#rid65">65,74,75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Two individual patient level meta-analyses failed to identify a significant increase in risk of VTE in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus chemotherapy versus chemotherapy alone [<a href="#rid65">65,75</a>]. In one of these meta-analyses (n = 1745 patients), the HR for VTE was 0.89, and in the second study (n = 6055 patients), the OR was 1.14, but neither result was statistically significant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, a significant risk of VTE in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> was shown in two other trial-level meta-analyses [<a href="#rid67">67,74</a>]. In one analysis of 7956 patients, the risk was significantly elevated; RR was 1.33, but it disappeared when examining these events per unit of time [<a href="#rid74">74</a>]. In the second analysis of 20,050 patients, the risk for venous adverse events with bevacizumab was 1.29 (95% CI 1.12-1.47) [<a href="#rid67">67</a>].</p><p></p><p>Thus, the association between <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and VTE remains uncertain.</p><p>The available data on <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> are limited. In a phase III trial comparing chemotherapy with and without aflibercept in patients with mCRC, the risk of all-grade VTE was 9.3 versus 7.3 percent with chemotherapy alone, and for grade 3 or 4 VTE  (<a class="graphic graphic_table graphicRef87383" href="/z/d/graphic/87383.html" rel="external">table 4</a>), it was 7.8 versus 6.2 percent [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H78097976"><span class="h5">Prevention and management</span><span class="headingEndMark"> — </span>There is not enough information available to recommend for or against the use of routine anticoagulation to prevent VTE in ambulatory cancer patients receiving, or about to receive, therapy with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>. We agree with the Clinical Practice Guidelines in Oncology from the National Comprehensive Cancer Network (NCCN) [<a href="#rid76">76</a>], which suggest stratifying recommendations for <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or anticoagulant prophylaxis in patients with cancer according to the presence or absence of risk factors for VTE. The NCCN does not consider the use of angiogenesis inhibitors to represent a risk factor for VTE in cancer patients, and we largely agree with this. (See  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Primary prevention'</a>.)</p><p>Prompt diagnosis and management is essential for patients who develop any grade of VTE during treatment  (<a class="graphic graphic_table graphicRef87383" href="/z/d/graphic/87383.html" rel="external">table 4</a>). Issues related to diagnosis and treatment of VTE in patients with malignancy are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">"Epidemiology and pathogenesis of acute pulmonary embolism in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a> and  <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a>.)</p><p>The United States Prescribing Information gives no recommendations for management of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> in patients who develop VTE while receiving the drug [<a href="#rid71">71,72</a>]. The decision to discontinue the angiogenesis inhibitor in such cases must be individualized. Continuation of bevacizumab or aflibercept with concurrent anticoagulation is a reasonable approach for patients who are clearly benefiting from the drug.</p><p>Angiogenesis inhibitors can be associated with an increased risk of hemorrhage, raising concern about the safety of therapeutic anticoagulation in patients who are being treated with these agents. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bleeding'</a>.)</p><p>However, the concurrent administration of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and therapeutic doses of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> appeared to be safe in a large retrospective pooled analysis (risk of bleeding 1.9 versus 1.2 percent in bevacizumab and control patients, respectively) [<a href="#rid75">75</a>]. Moreover, the majority of bleeds were minor epistaxis episodes, and the rates of severe (grade ≥3) bleeds were similar and infrequent in both groups (0.2 percent).</p><p>A similarly low rate of bleeding events with continued <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and full-dose anticoagulation was shown in another analysis of three studies, two conducted in patients with mCRC and one in advanced NSCLC [<a href="#rid77">77</a>]. There are no data on this approach for patients receiving <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>.</p><p>Low molecular weight heparins are generally preferred for the treatment of VTE in patients with cancer; their use has been associated with a lower recurrence risk than with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, without significantly increasing the rate of serious bleeding. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy", section on 'Principles of therapy'</a>.)</p><p class="headingAnchor" id="H244598758"><span class="h3">Ramucirumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">Ramucirumab</a> may be distinct among antiangiogenic agents in terms of risk for ATE and VTE. In a 2017 meta-analysis of individual patient safety data from six randomized placebo-controlled trials in a variety of malignancies, there was no definite increased risk with ramucirumab of either ATE (all-grade, RR 0.8, 95% CI 0.5-1.3; grade ≥3, RR 0.9, 95% CI 0.5-1.7) or VTE (all-grade, RR 0.7, 95% CI 0.5-1.1; grade ≥3, RR 0.7, 95% CI 0.4-1.2) [<a href="#rid27">27</a>]. Nevertheless, the United States Prescribing Information recommends discontinuation of the drug in the event of a serious ATE [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H291526542"><span class="h3">VEGFR tyrosine kinase inhibitors</span><span class="headingEndMark"> — </span>An increased risk of ATEs has also been shown in patients treated with antiangiogenic TKIs that prevent vascular endothelial growth factor receptor (VEGFR) signaling (relative to no treatment with a TKI), but as with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, the relationship to VTEs remains uncertain.</p><p class="headingAnchor" id="H1465984650"><span class="h4">Arterial thromboembolic events</span></p><p class="headingAnchor" id="H481364357"><span class="h5">Incidence</span><span class="headingEndMark"> — </span>The following data are available regarding the risk of ATEs in patients receiving antiangiogenic TKIs:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and meta-analysis that included 10,255 patients (87 percent with RCC) treated with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> in 10 studies (which included phase II and III trials as well as data from expanded access programs), the incidence of ATEs was 1.4 percent (RR 3.0 compared with controls) [<a href="#rid79">79</a>]. There were no differential impacts based on the underlying malignancy (RCC versus others) and specific TKI (sunitinib versus sorafenib).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a placebo-controlled phase III trial of 903 patients treated for advanced RCC, 2.9 percent of patients receiving <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> developed myocardial ischemia or infarction compared with 0.4 percent of patients receiving placebo [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, in a placebo-controlled randomized trial of <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> in advanced RCC, ATEs occurred in 3 percent of pazopanib-treated patients versus none in the placebo group [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Likewise, in a placebo-controlled trial of <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, ATEs occurred in 5 percent of the treated group versus 2 percent with placebo [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H78098047"><span class="h5">Management</span><span class="headingEndMark"> — </span>Both prevention and prompt management of an arterial thromboembolic event are critical. Prior to instituting therapy with antiangiogenic TKIs, predisposing cardiovascular risk factors (ie, hypertension, hyperlipidemia, and diabetes) should be aggressively managed. Baseline blood pressure should be controlled and the drug preferably not administered to patients with serious cardiovascular events within 6 to 12 months. Low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> prophylaxis is reasonable in high-risk patients such as those with a prior ATE [<a href="#rid83">83,84</a>].</p><p>Patients who develop an ATE of any grade while receiving an antiangiogenic TKI should discontinue the antiangiogenic treatment and the ATE should be managed according to usual standards of care. Reintroduction of the agent may be considered cautiously in select cases for patients who are clearly benefiting from therapy and who are willing to accept the uncertainty of risk from continued use of the TKI in this setting.</p><p class="headingAnchor" id="H1465984660"><span class="h4">Venous thromboembolic events</span></p><p class="headingAnchor" id="H1960840785"><span class="h5">Risk</span><span class="headingEndMark"> — </span>The association between antiangiogenic TKIs and VTE is uncertain. Semaxanib (SU5416), an investigational TKI that inhibits VEGF signaling, demonstrated a potential increase in VTEs in castration-resistant prostate cancer (11 percent), multiple myeloma (15 percent), and soft tissue sarcomas (15 percent) [<a href="#rid85">85-87</a>]. However, a meta-analysis of 7441 patients from nine phase III and eight phase II trials failed to demonstrate an increase in VTE in patients with solid tumors treated with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, or <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> [<a href="#rid88">88</a>]. The summary RR for all-grade VTEs was 1.10 (95% CI 0.73-1.66) compared with no TKI controls, and for high-grade VTEs, it was 0.85 (95% CI 0.58-1.25). There was no difference in risk based on tumor type or age.</p><p>Similar conclusions were reached in a second meta-analysis of 14 trials of <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, and <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a> [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H291526581"><span class="h5">Management</span><span class="headingEndMark"> — </span>There is not enough information available to recommend for or against the use of routine anticoagulation to prevent VTE in ambulatory cancer patients receiving, or about to receive, therapy with antiangiogenic TKIs. We agree with the Clinical Practice Guidelines in Oncology from the National Comprehensive Cancer Network (NCCN) [<a href="#rid76">76</a>], which suggest stratifying recommendations for <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or anticoagulant prophylaxis in patients with cancer according to the presence or absence of risk factors for VTE. The NCCN does not consider the use of angiogenesis inhibitors to represent a risk factor for VTE in cancer patients, and we largely agree with this. (See  <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Primary prevention'</a>.)</p><p>If a patient undergoing therapy with an antiangiogenic TKI develops a VTE, prompt diagnosis and treatment are essential. Issues related to diagnosis and treatment of VTE in patients with malignancy are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">"Epidemiology and pathogenesis of acute pulmonary embolism in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a> and  <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a>.)</p><p>A brief withdrawal of the TKI may be prudent, while anticoagulation is being attained. Resumption of the TKI once anticoagulation is established is reasonable assuming the patient is receiving antitumor benefit. However, the United States Prescribing Information for <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">tivozanib</a> recommends that the drug be discontinued in patients who develop severe or life-threatening VTE events [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H21640522"><span class="h2">Left ventricular dysfunction and myocardial ischemia</span></p><p class="headingAnchor" id="H3124015995"><span class="h3">Risk</span><span class="headingEndMark"> — </span>Declines in left ventricular function can be seen in patients treated with any of the VEGF-targeted therapies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and meta-analysis including 77 phase III trials, angiogenesis inhibitors were associated with a higher risk of cardiac ischemia (OR 2.83, 95% CI 1.72-4.65) and cardiac dysfunction (OR 1.35, 95% CI 1.06-1.70), but subgroup analyses did not reveal differences between VEGF ligand inhibitors and small molecule agents [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A total of 29,252 patients from 71 randomized controlled trials were included in a meta-analysis of VEGFR TKIs, which demonstrated a higher cardiac ischemia RR (RR 1.69, 95% CI 1.12-2.57), with the highest risks observed for <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> and patients with renal cancer [<a href="#rid24">24</a>]. Left ventricular systolic dysfunction was also increased after VEGFR TKIs (RR 2.53, 95% CI 1.79-3.57), with the highest risks observed for <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> and for those patients with hepatocellular cancer (HCC).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A total of 10,553 patients from 36 clinical trials were included in another meta-analysis of VEGF TKIs, which reported an overall incidence of all-grade and high-grade congestive heart failure (CHF) of 3.2 percent (95% CI 1.8-5.8 percent) and 1.4 percent (95% CI 0.9-2.3 percent), respectively, and the risk of developing all-grade (OR 2.37, 95% CI 1.76-3.20) and high-grade (OR 3.51, 95% CI 1.74-7.05) CHF also increased [<a href="#rid91">91</a>]. Interestingly, meta-regression suggested that CHF occurs early in treatment with VEGFR TKIs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and meta-analysis of 10,647 patients from 21 randomized trials of a variety of approved multitargeted VEGFR TKIs (no trials included <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> or <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>), heart failure of any grade developed in 138 of 5752 patients receiving VEGFR TKIs compared with 37 of 4895 in the non-TKI group (2.39 versus 0.75 percent). Serious (grade 3 or worse  (<a class="graphic graphic_table graphicRef58345" href="/z/d/graphic/58345.html" rel="external">table 5</a>)) heart failure occurred in 17 of 1426 patients receiving VEGFR TKIs compared with 8 of 1232 patients in the non-TKI group (1.19 versus 0.65 percent). The RR of all-grade and high-grade heart failure for the TKI versus no TKI arms was 2.69 (95% CI 1.86-3.87) and 1.65 (95% CI 0.73-3.70), respectively. In this analysis, there was no difference in the risk of heart failure with the relatively specific TKI <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> as compared with nonspecific TKIs such as <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, and <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> [<a href="#rid92">92</a>]. However, cardiac failure, potentially fatal, has been observed in patients treated with axitinib [<a href="#rid90">90</a>].</p><p></p><p class="headingAnchor" id="H619659074"><span class="h3">Bevacizumab</span><span class="headingEndMark"> — </span>Heart failure associated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> has been sporadically reported in several trials of bevacizumab given in conjunction with anthracyclines or <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> in women with metastatic breast cancer, an indication for which bevacizumab is no longer approved [<a href="#rid93">93-95</a>]. It has not been reported in patients treated with bevacizumab for other advanced cancers.</p><p>In contrast with heart failure, ischemic cardiac events are increased in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>. (See <a class="local">'Arterial thromboembolic events'</a> above.)</p><p>The specific incidence of cardiac ischemia was addressed in a meta-analysis of five controlled trials conducted in patients with mCRC or advanced RCC that separated out risks of cardiac events and strokes [<a href="#rid68">68</a>]. The summary RR of high-grade cardiac ischemia in patients receiving <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> was 2.14 (95% CI 1.12-4.08), and the overall incidence was 1.5 percent (95% CI 1-2.1 percent).</p><p class="headingAnchor" id="H21640884"><span class="h3">Specific VEGFR tyrosine kinase inhibitors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Axitinib</strong> – In a randomized phase III trial, heart failure was reported in 6 of 339 patient treated with <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> (2 percent, two fatal), versus 3 of 355 of those treated with <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> (1 percent, one fatal) [<a href="#rid96">96</a>]. Major adverse cardiovascular events occurred in 7 percent of patients with advanced renal cell cancer treated with axitinib plus <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> in the JAVELIN Renal 101 trial; these events included death due to cardiac events (1.4 percent), grade 3 or 4 myocardial infarction (2.8 percent), and grade 3 or 4 heart failure (1.8 percent) [<a href="#rid97">97</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong> – In a placebo-controlled trial in patients with advanced thyroid cancer, cardiac dysfunction (decreased ejection fraction, cardiac failure, or pulmonary edema) was reported in 7 percent versus 2 percent in the placebo group [<a href="#rid82">82</a>]. The majority of cases were findings of decreased ejection fraction by echocardiography.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pazopanib</strong> – In trials of <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, cardiac dysfunction (decreased LVEF and clinical heart failure) has been observed. As an example, in a trial in advanced soft tissue sarcoma, myocardial dysfunction (symptomatic, or ≥15 percent absolute decline in LVEF compared with baseline, or decrease in LVEF to ≥5 percent below the lower limit of normal) was observed in 6.7 percent of patients treated with pazopanib compared with 2.4 percent of placebo-treated patients [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regorafenib</strong> – In a placebo-controlled clinical trial in patients with metastatic colorectal cancer, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> was associated with an increased incidence of myocardial ischemia and infarction (1.2 versus 0.4 percent with placebo) [<a href="#rid99">99</a>]. Heart failure has not been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ripretinib</strong> – <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">Ripretinib</a> is an inhibitor of KIT and PDGFRA kinases that is approved as a fourth-line agent for treatment of advanced gastrointestinal stromal tumors; in vitro, it also inhibits VEGFR2. (See  <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Ripretinib'</a>.)</p><p></p><p class="bulletIndent1">Heart failure has occurred in approximately 1 percent of treated patients, and grade 3 decreased ejection fraction  (<a class="graphic graphic_table graphicRef128231" href="/z/d/graphic/128231.html" rel="external">table 6</a>) has been seen in 2 to 3 percent [<a href="#rid100">100,101</a>]. Whether these changes reflect inhibition of VEGFR2, KIT, PDGFRA, or a combination of these targets remains unclear. (See  <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Ripretinib'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sunitinib</strong><strong> and </strong><strong>sorafenib</strong> – In retrospective series and clinical trials, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> has been associated with a decline in left ventricular ejection fraction (LVEF) in up to 28 percent of treated patients and clinical heart failure in 3 to 15 percent [<a href="#rid13">13,14,102-104</a>].</p><p></p><p class="bulletIndent1">In the pivotal randomized trial that led to approval of <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> for advanced renal cell cancer, 21 percent of patients experienced a decline in LVEF, but this was symptomatic in only 10 percent [<a href="#rid103">103</a>]. All cases were reversible and not associated with an adverse clinical outcome. In an early study of patients receiving sunitinib for a gastrointestinal stromal tumor (GIST), left ventricular dysfunction developed in 10 versus 3 percent of the sunitinib and placebo-treated patients, respectively [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1">In a meta-analysis of the published literature that included 6936 patients receiving <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> for a variety of oncologic indications and who had regular cardiac function monitoring, the summary incidence of all grades of heart failure was 4.1 percent (95% CI 1.5-10.6 percent) and of grade 3 or 4 heart failure  (<a class="graphic graphic_table graphicRef58345" href="/z/d/graphic/58345.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef99987" href="/z/d/graphic/99987.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef99985" href="/z/d/graphic/99985.html" rel="external">table 8</a>) was 1.5 percent (95% CI 0.8-3.0 percent) [<a href="#rid105">105</a>]. There were no differences in subgroups of patients receiving sunitinib for renal cell versus nonrenal cell cancer indications. Both hypertension and a history of coronary artery disease are thought to increase the risk of sunitinib cardiotoxicity.</p><p></p><p class="bulletIndent1">However, these data from clinical trials probably underestimate the risk of LVEF decline and clinical heart failure [<a href="#rid106">106</a>]. It is now thought that the vast majority of patients treated with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (29 of 36 in one analysis [<a href="#rid13">13</a>]) experience an LVEF drop during therapy that approximately one in five have LVEF reductions of 15 percent or more, that 11 percent of patients receiving repeated cycles of sunitinib a cardiovascular event, mostly heart failure, and that preexisting hypertension and coronary artery disease are risk factors for cardiac toxicity [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">Patients who have had a cardiovascular event (eg, myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism) within 12 months prior to <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> administration have been excluded from the sunitinib studies. If sunitinib is administered to such patients, they should be carefully monitored for clinical signs and symptoms of heart failure, and undergo periodic reevaluation of LVEF during therapy.</p><p></p><p class="bulletIndent1">Less data on cardiotoxicity are available with <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, but the risk seems to be lower than with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one phase III trial of patients treated for advanced renal cell cancer, 2.9 percent of patients receiving <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> developed myocardial ischemia or infarction compared with 0.4 percent of patients receiving placebo [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a second trial of <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> in advanced HCC, the incidence of cardiac ischemia or infarction with sorafenib was 2.7 versus 1.3 percent in the placebo group [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1">A major problem with defining the precise rate of cardiotoxicity associated with both <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> and <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> and its reversibility is that phase III trials have not pursued cardiac endpoints, and the identification of cardiac side effects with both drugs has predominantly been based on the occurrence of clinical symptoms. Potentially, the most comprehensive data on the range and frequency of cardiotoxicity with these drugs come from an observational series of 86 consecutive patients with renal cell cancer who were treated with either sunitinib or sorafenib at a single Austrian center over a 15-month period [<a href="#rid108">108</a>]. During treatment, 25 of 74 assessable patients (34 percent, including 11 receiving sunitinib and 14 treated with sorafenib) experienced a cardiovascular event, as defined by new elevation in cardiac enzymes, symptomatic arrhythmia requiring treatment, new left ventricular dysfunction, or acute coronary syndrome. Reported electrocardiogram (ECG) changes included changes in rhythm, conduction disturbance, change in axis or QRS amplitude, ST or T wave changes, and corrected QT (QTc) prolongation (which has been reported by others with sunitinib). (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1">All symptomatic patients discontinued use of the TKI and began medical cardiovascular treatment. All recovered, although three had persisting abnormal cardiac enzymes through the entire TKI treatment period.</p><p></p><p class="bulletIndent1">However, the high rate of cardiotoxicity in this series could have been related to the broad (and unconventional) definition of a cardiac event. In a preliminary report of cardiac toxicities with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> use for the adjuvant therapy of RCC (ASSURE phase III trial), cardiac function in patients starting with normal LVEF was not impaired significantly over placebo [<a href="#rid109">109</a>]. Ischemic events were uncommon and not clearly associated with treatment. However, it should be noted that cardiac function was assessed at the six month time point and, therefore, excluded many patients who stopped treatment earlier due to side effects.</p><p></p><p class="bulletIndent1">The nature of myocardial damage from antiangiogenic TKI treatment has not been extensively investigated, although hypotheses as to an underlying off-target pathophysiologic mechanism of cardiotoxicity caused by <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> and <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> have been proposed [<a href="#rid110">110-112</a>].</p><p></p><p class="headingAnchor" id="H1465984881"><span class="h3">Monitoring and management</span><span class="headingEndMark"> — </span>Baseline assessment of LVEF by echocardiogram or MUGA scan and an ECG are suggested variably by the manufacturers of the different agents. Some have suggested that patients receiving these drugs be treated as "stage A" heart failure patients (ie, at risk for heart failure), but without structural heart disease or symptoms [<a href="#rid113">113</a>]. Year 2013 guidelines for management of stage A heart failure from the American Heart Association suggest that it may be reasonable to evaluate those who are receiving potentially cardiotoxic agents for left ventricular dysfunction [<a href="#rid114">114</a>].</p><p>However, obtaining a baseline assessment of LVEF in all patients receiving these drugs is not supported by compelling data. We obtain a baseline LVEF evaluation only in older adult patients and those with a history of prior cardiovascular disease or prior anthracycline exposure. Caution and close serial monitoring of LVEF is warranted during therapy with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and VEGFR TKIs for older adult patients and for those with a history of poorly controlled hypertension, heart disease, or anthracycline exposure. However, in our view, routine serial monitoring of ECGs and cardiac enzymes during therapy in the absence of symptoms is not warranted for other patients. The clinical significance of asymptomatic increases in cardiac enzymes or ECG changes to detect myocardial ischemia remains undefined. Clinicians should maintain a low threshold for cardiac evaluation in symptomatic patients.</p><p>The United States Prescribing Information offers specific interventions for patients receiving the following antiangiogenic agents who develop LV dysfunction or myocardial ischemia [<a href="#rid90">90</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sunitinib</strong> – Discontinue therapy in the presence of clinical manifestations of heart failure. Interrupt therapy and/or dose reduce in patients without clinical evidence of heart failure but with an ejection fraction &lt;50 percent but &gt;20 percent below baseline or below the lower limit of normal if baseline ejection fraction was not obtained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sorafenib</strong> – Temporarily or permanently discontinue therapy in any patient who develops cardiac ischemia and/or infarction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong> – Withhold therapy for any grade 3 cardiac dysfunction. Discontinue for grade 4 cardiac dysfunction  (<a class="graphic graphic_table graphicRef99985" href="/z/d/graphic/99985.html" rel="external">table 8</a> and <a class="graphic graphic_table graphicRef99987" href="/z/d/graphic/99987.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef58345" href="/z/d/graphic/58345.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regorafenib</strong> – Withhold for new or acute onset cardiac ischemia or infarction. Resume only after resolution of acute cardiac ischemic events and if the potential benefits outweigh the risks of further cardiac ischemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">Ripretinib</a> – Permanently discontinue for grade 3 or 4 LV dysfunction. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antiangiogenic agents</strong> – Guidance is not available for the other agents of this class. However, in general we hold the TKI for cardiotoxicity, and if the event was not major and the patient recovered, we (and others [<a href="#rid115">115</a>]) would consider restarting therapy if there was evidence of clinical benefit. Some patients who recover from left ventricular dysfunction may go on to tolerate re-exposure for long periods of time [<a href="#rid115">115</a>]. For patients who develop heart failure during treatment, it is also reasonable to switch to an alternative, less cardiotoxic anti-VEGF agent, if one is available (eg, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> or <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> for patients with RCC who develop heart failure while receiving <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>).</p><p></p><p class="headingAnchor" id="H2667890951"><span class="h2">Aortic dissections and aneurysms</span><span class="headingEndMark"> — </span>Accumulating case reports link the use of VEGFR TKIs and <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> with abnormal structural changes of artery walls, resulting in aortic dissections and aneurysms [<a href="#rid116">116-127</a>]. The largest series is a pharmacovigilance study derived from VigiBase, the World Health Organization's centralized database of medication-related adverse drug reactions (ADRs) spontaneously reported by patients and clinicians from July 18, 2005 to January 19, 2019 [<a href="#rid127">127</a>]. Of the 217,664 ADRs potentially related to receipt of one of 14 antiangiogenic drugs, 494 (0.23 percent) were artery dissections or aneurysms. The antiangiogenic agent was bevacizumab in 45 percent, a VEGFR TKI in 36 percent, a mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitor in 12 percent, and <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> in 2 percent. Of the VEGFR TKIs, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> was the most common agent reported, while <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> was associated with the fewest cases (14.4 versus 1.4 percent). The time to onset of the ADR varied widely (median 89 days, interquartile interval 27 to 212 days). The dissection or aneurysm involved the aorta in 42 percent of cases, the cerebral arteries in 35 percent, and other/nonspecified arteries in the remainder. Overall, 24 percent of cases were fatal and 18 percent were life-threatening.</p><p>Although cases are described in the absence of hypertension, treatment-related hypertension may increase the risk by contributing to a damaged endothelium. In a report from the Japanese Adverse Drug Event Report database that included over 16,000 patients treated with VEGF pathway inhibitors and 59 patients with aortic dissection, the likelihood of aortic dissection with a VEGF pathway inhibitor after adjustment for concomitant hypertension remained high (adjusted OR 19.4, 95% CI 10.2-40.8) [<a href="#rid117">117</a>]. By comparison, the adjusted OR for hypertension alone (without a VEGF pathway inhibitor) was only 3.8 (95% CI 2.3-6.4). These reports led Health Canada to issue a safety alert to inform health care professionals about this risk [<a href="#rid128">128</a>]; a similar alert was recommended to be added to product labeling by the European Medicines Agency. </p><p>This observation emphasizes the need to control hypertension in patients on VEGFR TKIs and to have a high index of suspicion for aortic dissection in patients presenting with otherwise unexplained chest or abdominal pain. (See  <a class="medical medical_review" href="/z/d/html/8190.html" rel="external">"Clinical features and diagnosis of acute aortic dissection", section on 'Symptoms and signs'</a>.)</p><p class="headingAnchor" id="H386772"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span>Bleeding associated with antiangiogenic therapy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H1063205212"><span class="h1">CLASS SIDE EFFECTS OF VEGF TYROSINE KINASE INHIBITORS</span></p><p class="headingAnchor" id="H1063204941"><span class="h2">Prolongation of the QTc interval and cardiac arrhythmias</span></p><p class="headingAnchor" id="H1655565242"><span class="h3">Risk</span><span class="headingEndMark"> — </span>Many drugs delay cardiac repolarization, an effect that is reflected on the surface electrocardiogram (ECG) by a prolonged heart rate corrected QT (QTc) interval. Although a prolonged QTc interval is not immediately harmful, it can be associated with potentially fatal cardiac arrhythmias. The ventricular tachyarrhythmia most typically triggered is of a unique form, known as torsades de pointes, which is most often transient, but when sustained, can give rise of symptoms of impaired cerebral circulation or degenerate into ventricular fibrillation, usually with a fatal outcome. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a> and  <a class="medical medical_review" href="/z/d/html/1009.html" rel="external">"Congenital long QT syndrome: Pathophysiology and genetics", section on 'Pathophysiology'</a>.)</p><p>The risk of QTc prolongation with vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs) has been addressed in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 29,252 patients from 71 randomized controlled trials, QTc prolongation (relative risk [RR] 6.25, 95% CI 3.44-11.38) was reported with VEGF TKIs [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional data are available from a trial-level meta-analysis of 6548 patients from 18 eligible randomized controlled trials in which one of the arms was a US Food and Drug Administration (FDA)-approved VEGF receptor TKI (there were no trials of <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, or <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>) [<a href="#rid129">129</a>]. Overall, 4.4 and 0.83 percent of patients exposed to a VEGF receptor TKI had all-grade and high-grade QTc prolongation, respectively. The RR for all-grade and high-grade QTc prolongation for the TKI versus no TKI arms was 8.66 (95% CI 4.92-15.2) and 2.69 (95% CI 1.33-5.44), respectively, with most of the events being asymptomatic QTc prolongation. On subgroup analysis, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> and <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a> were both associated with a statistically significant risk of QTc prolongation, while the increased RR seen with <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> and <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> was not statistically significant. Higher doses of vandetanib were associated with a greater risk (RR 12.2 versus 3.6 for lower doses). The rate of serious arrhythmias including torsades de pointes did not seem to be higher in patients who developed high-grade QTc prolongation. The risk of QTc prolongation was independent of the duration of therapy.</p><p></p><p class="headingAnchor" id="H383759128"><span class="h3">Specific agents</span><span class="headingEndMark"> — </span>Of the VEGF receptor TKIs, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> have been most convincingly associated with QTc prolongation, while the risk with other VEGF receptor TKIs, including <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, is less certain [<a href="#rid115">115</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong> – In a placebo-controlled trial, approximately 9 percent of lenvatinib-treated patients developed QTc interval prolongation versus 2 percent in the control group; the incidence of grade 3 or greater QTc prolongation was 2 percent versus non in the placebo group. The United States Prescribing Information recommends monitoring ECGs in patients with congenital long QT syndrome, heart failure, bradyarrhythmias, or those taking drugs known to prolong the QT interval  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 9</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sunitinib</strong> – <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">Sunitinib</a> also has a dose-dependent effect on the QTc interval [<a href="#rid108">108,115,130,131</a>]. In contrast, the effect of <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> on changes in the QTc interval appears modest and unlikely to be of clinical significance [<a href="#rid115">115,132</a>].</p><p></p><p class="bulletIndent1">Specific guidelines for monitoring with ECGs during <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> therapy and managing the dose in patients who develop QTc prolongation are lacking. In general, we obtain a baseline ECG in patients treated with sunitinib and monitor with ECGs during therapy only if the patient is also receiving therapy with other drugs that have the potential to prolong the QTc interval  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 9</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vandetanib</strong> – In clinical trials, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a> has been associated with prolongation of the QTc interval  (<a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">waveform 1</a>), torsades de pointes, and sudden death [<a href="#rid115">115,133,134</a>]. The magnitude of risk can be illustrated by a meta-analysis of nine phase II or III trials of vandetanib in a variety of malignancies [<a href="#rid134">134</a>]. The overall incidence of all-grade (&gt;0.45 seconds) and high-grade (&gt;0.5 seconds or symptomatic and requiring treatment) QTc interval prolongation was 16.4 and 3.7 percent, respectively, among non-thyroid cancer patients (predominantly breast and lung cancer), and 18 and 12 percent, respectively, among thyroid cancer patients who received treatment for a substantially longer period of time (median 18.8 versus 1.8 to 3 months) [<a href="#rid134">134</a>].</p><p></p><p class="bulletIndent1">Largely because of its cardiovascular risk, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a> is only available through a restricted distribution program (the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.caprelsarems.com%2Findex.asp&amp;token=A4rNrjoOj2Gkzpl8CyA25kv6qTODrQKY0i6QQmdl9W%2BPXVKa%2BMOagYhjx8dxBAYE&amp;TOPIC_ID=14250" target="_blank">Caprelsa Risk Evaluation and Mitigation Strategy [REMS] program</a>). (See  <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">"Medullary thyroid cancer: Systemic therapy and immunotherapy", section on 'Vandetanib'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">Vandetanib</a> should not be initiated in a patient with a QTc interval &gt;450 milliseconds (ms) [<a href="#rid135">135</a>]. Because of the risk of cardiotoxicity, the United States Prescribing Information includes a black box warning to correct hypocalcemia, hypokalemia, and/or hypomagnesemia prior to drug administration. In addition, given the long half-life of the drug (19 days), ECGs are recommended to monitor the QT interval at baseline, at two to four weeks, and 8 to 12 weeks after starting treatment, and every three months thereafter. Monitoring of serum potassium, calcium, and magnesium levels as well as TSH is recommended on the same schedule. Concurrent administration of drugs known to prolong the QTc interval should be avoided  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 9</a>). (See <a class="local">'Monitoring and management'</a> below.)</p><p></p><p class="bulletIndent1">Patients who develop a QTc interval greater than 500 ms during treatment should stop taking the drug until the QTc returns to &lt;450 ms; dosing should be resumed at a reduced dose.</p><p></p><p class="headingAnchor" id="H1556580909"><span class="h3">Monitoring and management</span><span class="headingEndMark"> — </span>Specific guidelines for assessing and monitoring the QTc interval and recommendations for managing the drug based on the grade of toxicity  (<a class="graphic graphic_table graphicRef91251" href="/z/d/graphic/91251.html" rel="external">table 10</a>) are available for patients receiving <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a> and <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> [<a href="#rid90">90</a>]. Formal guidelines are not available for any of the other antiangiogenic TKIs.</p><p>The optimal formula to use to calculate the QTc interval in patients receiving chemotherapy drugs that have the potential to alter the QTc interval is debated [<a href="#rid136">136-138</a>]. The United States Prescribing Information for all of the VEGF receptor TKIs does not specify use of any one formula over another. (See  <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management", section on 'ECG findings'</a>.)</p><p>However, some have recommended preferential use of the Framingham or Fridericia formulae (<a class="calc calc_professional" href="/z/d/html/13459.html" rel="external">calculator 1</a>) [<a href="#rid136">136,138</a>].</p><p>For any patient receiving therapy with an antiangiogenic TKI, careful review of concomitant medications is warranted, especially drugs that are associated with increased QTc  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 9</a>). Patients with a history of QT interval prolongation, those who are taking antiarrhythmics, and those with relevant preexisting cardiac disease, bradycardia, or electrolyte disturbances may be more prone to developing a prolonged QTc. Concomitant treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 11</a>), which may increase plasma concentrations of antiangiogenic TKIs, may require a dose reduction of the TKI.</p><p>Management of the patient who develops an arrhythmia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H386790"><span class="h1">AGENT-SPECIFIC EFFECTS</span></p><p class="headingAnchor" id="H387595"><span class="h2">Thrombotic microangiopathy</span><span class="headingEndMark"> — </span>Rarely, cases of drug-induced thrombotic microangiopathy (DITMA) have been reported with specific antiangiogenic agents (eg, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>). Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Antiangiogenic agents'</a> and  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p class="headingAnchor" id="H21640979"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification of antiangiogenic agents </strong>– Antiangiogenic agents (systemic medications that inhibit angiogenesis) have unique toxicities that differ from those of cytotoxic chemotherapy. Toxicities may be specific to the drug class or to the agent itself. Classes of antiangiogenic agents include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ligand inhibitors</strong> –<strong> </strong>These agents bind to and inhibit ligand binding to the vascular endothelial growth factor (VEGF) receptor, thereby preventing activation of the receptor. Examples include <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a>, and <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Receptor tyrosine kinase inhibitors (TKIs)</strong> – These agents block the intracellular domain of the VEGF receptor (VEGFR). Examples include <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">ponatinib</a>, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">tivozanib</a>, and <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular effects of antiangiogenic agents</strong> – Cardiovascular effects of antiangiogenic agents may occur early and may be independent of dose. Some can be serious and potentially fatal. A multidisciplinary approach that includes the treating oncologist and cardiologist (preferably with expertise in cardio-oncology) and careful selection of patients for therapy with angiogenesis inhibitors, as well as close monitoring and prompt intervention, is necessary to reduce the risks posed by these agents. (See <a class="local">'Introduction'</a> above and <a class="local">'Risk of fatality'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypertension</strong> – All commercially available angiogenesis inhibitors have been implicated in the development of hypertension. The overall incidence of hypertension is approximately 22 to 25 percent, with severe hypertension in 7 to 8 percent. Systolic or diastolic hypertension may represent a surrogate marker for response or improved outcomes with both <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and the antiangiogenic TKIs. (See <a class="local">'Incidence and characteristics'</a> above and <a class="local">'Association with antitumor efficacy'</a> above.)</p><p></p><p class="bulletIndent2">Recommendations for monitoring and management of hypertension from the National Cancer Institute (NCI) Cardiovascular Toxicities Panel include (see <a class="local">'Monitoring and management'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Perform a pretreatment evaluation, including formal risk assessment for potential cardiovascular complications.</p><p class="bulletIndent3"><span class="glyph">-</span>Identify and treat preexisting hypertension before using these agents.</p><p class="bulletIndent3"><span class="glyph">-</span>Actively monitor blood pressure during treatment, with more frequent measurement in the first several weeks of therapy.</p><p class="bulletIndent3"><span class="glyph">-</span>Treat hypertension, with a goal blood pressure of 130/80 mmHg for most patients, lower in those with specific preexisting cardiovascular risk factors, such as diabetes or chronic kidney disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Arterial thrombotic events</strong> – An increased risk for arterial thromboembolic events (ATEs) has been linked to the use of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>, and a number of antiangiogenic TKIs. The risk appears to be highest in patients with a prior history of an ATE and, in some reports, in those over age 65; bevacizumab should be used with caution in this group. The drug should be discontinued for grade 3 or higher  (<a class="graphic graphic_table graphicRef87383" href="/z/d/graphic/87383.html" rel="external">table 4</a>) new or worsened ATEs during bevacizumab therapy. Continuation with concurrent anticoagulation might be considered in selected patients who are clearly benefiting from bevacizumab and who are willing to accept the uncertainty of risk from continued use of bevacizumab in this setting. (See <a class="local">'Arterial thromboembolic events'</a> above.)</p><p></p><p class="bulletIndent2">For patients being considered for an antiangiogenic TKI, low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> prophylaxis is reasonable for high-risk patients (eg, a prior ATE). Patients who develop an ATE should discontinue the TKI, and the ATE should be managed according to current standards of care. Reintroduction of the TKI may be considered cautiously in selected cases if the patient was deriving benefit from the drug. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Venous thromboembolism (VTE)</strong> – The aggregate of data suggests <strong>no</strong> significant increase in the risk of VTE with VEGF-targeted therapy, with the possible exception of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>. (See <a class="local">'Venous thromboembolism'</a> above and <a class="local">'Venous thromboembolic events'</a> above.)</p><p></p><p class="bulletIndent2">The decision to continue <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in a patient who develops a VTE during therapy must be individualized. Continuation of bevacizumab with concurrent anticoagulation is a safe approach for patients who are clearly benefiting from bevacizumab (see <a class="local">'Prevention and management'</a> above). If a patient undergoing therapy with an antiangiogenic TKI develops a VTE, a brief withdrawal of the TKI may be prudent while anticoagulation is being attained. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LV dysfunction</strong> – Declines in left ventricular ejection fraction (LVEF) can be seen in patients treated with VEGF-targeted therapies; predominantly in patients treated with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. Myocardial ischemia has been seen in patients treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, and <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>.</p><p></p><p class="bulletIndent2">Baseline assessment of LVEF prior to treatment is warranted in older adults and in those with prior cardiovascular disease or anthracycline exposure. Caution and close serial monitoring of LVEF are warranted during therapy with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and antiangiogenic TKIs in older adults and those with prior hypertension, heart disease, or anthracycline exposure. (See <a class="local">'Left ventricular dysfunction and myocardial ischemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aortic dissection and aneurysm</strong> – Accumulating case reports link VEGF receptor (VEGFR) TKIs and <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> with aortic dissections and aneurysms; uncontrolled hypertension may increase this risk. This observation emphasizes the need to control hypertension in patients on VEGFR TKIs and to have a high index of suspicion for aortic dissection in patients presenting with otherwise unexplained chest or abdominal pain. (See <a class="local">'Aortic dissections and aneurysms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>QTc prolongation</strong> – Prolongation of the corrected QT (QTc) interval has been described with <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a>, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, but not with other antiangiogenic TKIs. Specific guidelines for managing QTc prolongation during vandetanib and lenvatinib therapy are available. (See <a class="local">'Prolongation of the QTc interval and cardiac arrhythmias'</a> above.)</p><p></p><p class="bulletIndent2">For any patient receiving therapy with an antiangiogenic TKI, careful review of concomitant medications is warranted, especially drugs that are associated with increased QTc  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 9</a>). Patients with a history of QTc interval prolongation, those taking antiarrhythmics, and those with preexisting cardiac disease, bradycardia, or electrolyte disturbances may be more prone to developing a prolonged QTc. Concomitant treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 11</a>), which may increase concentrations of the antiangiogenic TKI, may require a dose reduction of the TKI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other adverse effects</strong> – Non-cardiovascular toxicities and nephrotoxicity of antiangiogenic agents are presented separately. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Antiangiogenic agents'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182.</a></li><li><a class="nounderline abstract_t">Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305:487.</a></li><li><a class="nounderline abstract_t">Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012; 30:871.</a></li><li><a class="nounderline abstract_t">Herrmann J, Yang EH, Iliescu CA, et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation 2016; 133:1272.</a></li><li><a class="nounderline abstract_t">Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol 2018; 2:13.</a></li><li><a class="nounderline abstract_t">Kappers MH, de Beer VJ, Zhou Z, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59:151.</a></li><li><a class="nounderline abstract_t">Duran JM, Makarewich CA, Trappanese D, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res 2014; 114:1700.</a></li><li><a class="nounderline abstract_t">Sourdon J, Lager F, Viel T, et al. Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism. Theranostics 2017; 7:2757.</a></li><li><a class="nounderline abstract_t">Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol 2013; 168:2453.</a></li><li><a class="nounderline abstract_t">Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691.</a></li><li><a class="nounderline abstract_t">Chintalgattu V, Rees ML, Culver JC, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 2013; 5:187ra69.</a></li><li><a class="nounderline abstract_t">Steeghs N, Rabelink TJ, op 't Roodt J, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 2010; 21:1100.</a></li><li><a class="nounderline abstract_t">Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011.</a></li><li><a class="nounderline abstract_t">Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009; 20:1535.</a></li><li><a class="nounderline abstract_t">Sivendran S, Liu Z, Portas LJ Jr, et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012; 38:919.</a></li><li><a class="nounderline abstract_t">Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107:1359.</a></li><li><a class="nounderline abstract_t">Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274:H1054.</a></li><li><a class="nounderline abstract_t">Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005; 90:315.</a></li><li><a class="nounderline abstract_t">Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004; 255:538.</a></li><li><a class="nounderline abstract_t">Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56:1131.</a></li><li><a class="nounderline abstract_t">Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24:1329.</a></li><li><a class="nounderline abstract_t">Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20:807.</a></li><li><a class="nounderline abstract_t">Abdel-Qadir H, Ethier JL, Lee DS, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 2017; 53:120.</a></li><li><a class="nounderline abstract_t">Totzeck M, Mincu RI, Mrotzek S, et al. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol 2018; 25:482.</a></li><li><a class="nounderline abstract_t">Liu B, Ding F, Liu Y, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016; 7:67661.</a></li><li><a class="nounderline abstract_t">An MM, Zou Z, Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010; 66:813.</a></li><li><a class="nounderline abstract_t">Arnold D, Fuchs CS, Tabernero J, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 2017; 28:2932.</a></li><li><a class="nounderline abstract_t">Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48:9.</a></li><li><a class="nounderline abstract_t">Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9:117.</a></li><li><a class="nounderline abstract_t">Qi WX, Lin F, Sun YJ, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 2013; 71:431.</a></li><li><a class="nounderline abstract_t">Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.</a></li><li class="breakAll">Motzer RJ, Hutson TE, Reeves J, et al. Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC); Results of the COMPARZ trial. European Society of Medical Oncology Congress LBA8, Vienna, Austria. September 28 to October 2, 2012.</li><li><a class="nounderline abstract_t">Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372:621.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499.</a></li><li><a class="nounderline abstract_t">Hamnvik OP, Choueiri TK, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121:311.</a></li><li><a class="nounderline abstract_t">Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15:6250.</a></li><li><a class="nounderline abstract_t">Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358:95.</a></li><li><a class="nounderline abstract_t">Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596.</a></li><li><a class="nounderline abstract_t">Schneider BP, Li L, Shen F, et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 2014; 111:1241.</a></li><li><a class="nounderline abstract_t">Sibertin-Blanc C, Mancini J, Fabre A, et al. Vascular Endothelial Growth Factor A c.*237C&gt;T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Dig Liver Dis 2015; 47:331.</a></li><li><a class="nounderline abstract_t">Mir O, Coriat R, Cabanes L, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011; 16:1325.</a></li><li><a class="nounderline abstract_t">Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28:949.</a></li><li><a class="nounderline abstract_t">Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672.</a></li><li><a class="nounderline abstract_t">Ryanne Wu R, Lindenberg PA, Slack R, et al. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer 2009; 40:101.</a></li><li><a class="nounderline abstract_t">Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20:227.</a></li><li><a class="nounderline abstract_t">Goodwin R, Ding K, Seymour L, et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010; 21:2220.</a></li><li><a class="nounderline abstract_t">Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103:763.</a></li><li><a class="nounderline abstract_t">Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol 2013; 36:319.</a></li><li><a class="nounderline abstract_t">Donskov F, Michaelson MD, Puzanov I, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer 2015; 113:1571.</a></li><li><a class="nounderline abstract_t">Wick A, Schäfer N, Dörner N, et al. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol 2010; 97:157.</a></li><li><a class="nounderline abstract_t">Hurwitz HI, Douglas PS, Middleton JP, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013; 18:273.</a></li><li><a class="nounderline abstract_t">Duffaud F, Sleijfer S, Litière S, et al. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Eur J Cancer 2015; 51:2615.</a></li><li><a class="nounderline abstract_t">Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 2009; 27:6152.</a></li><li><a class="nounderline abstract_t">Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66:357.</a></li><li><a class="nounderline abstract_t">Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291:2441.</a></li><li><a class="nounderline abstract_t">Bamias A, Manios E, Karadimou A, et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer 2011; 47:1660.</a></li><li><a class="nounderline abstract_t">Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013; 23:104.</a></li><li><a class="nounderline abstract_t">Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27:4865.</a></li><li><a class="nounderline abstract_t">Mir O, Mouthon L, Alexandre J, et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 2007; 99:85.</a></li><li><a class="nounderline abstract_t">Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49:568.</a></li><li><a class="nounderline abstract_t">González-Pacheco FR, Deudero JJ, Castellanos MC, et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol 2006; 291:H1395.</a></li><li><a class="nounderline abstract_t">Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788.</a></li><li><a class="nounderline abstract_t">Tebbutt NC, Murphy F, Zannino D, et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 2011; 22:1834.</a></li><li class="breakAll">www.fda.gov/medwatch/SAFETY/2004/safety04.htm#avastin (Accessed on May 15, 2012).</li><li><a class="nounderline abstract_t">Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232.</a></li><li><a class="nounderline abstract_t">Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011; 22:1404.</a></li><li><a class="nounderline abstract_t">Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20,000 Patients. J Am Heart Assoc 2017; 6:e006278.</a></li><li><a class="nounderline abstract_t">Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49:287.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Khayat D, Verslype C, et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer 2013; 49:17.</a></li><li><a class="nounderline abstract_t">Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 2012; 18:6023.</a></li><li class="breakAll">FDA-approved manufacturer's package insert for bevacizumab available online at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e#section-5-5 (Accessed on December 14, 2012).</li><li class="breakAll">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6725df6-50ee-4b0a-b900-d02ba634395d#section-5.6 (Accessed on February 01, 2013).</li><li class="breakAll">Common Toxicity Criteria of the National Cancer Institute available online at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed on May 15, 2012).</li><li><a class="nounderline abstract_t">Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277.</a></li><li><a class="nounderline abstract_t">Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011; 29:1757.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Leighl NB, Bennouna J, Yi J, et al. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 2011; 104:413.</a></li><li class="breakAll">US Food and Drug Administration (FDA)-approved prescribing information for ramucirumab available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477lbl.pdf (Accessed on April 25, 2014).</li><li><a class="nounderline abstract_t">Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28:2280.</a></li><li><a class="nounderline abstract_t">Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.</a></li><li><a class="nounderline abstract_t">Sternberg CN, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2016; 27:(suppl; absr 5021).</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf?et_cid=35470087&amp;et_rid=907466112&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f206947s000lbl.pdf (Accessed on February 20, 2015).</li><li><a class="nounderline abstract_t">Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:234S.</a></li><li><a class="nounderline abstract_t">Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292:1867.</a></li><li><a class="nounderline abstract_t">Stadler WM, Cao D, Vogelzang NJ, et al. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004; 10:3365.</a></li><li><a class="nounderline abstract_t">Zangari M, Anaissie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10:88.</a></li><li><a class="nounderline abstract_t">Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004; 10:5732.</a></li><li><a class="nounderline abstract_t">Sonpavde G, Je Y, Schutz F, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2013; 87:80.</a></li><li><a class="nounderline abstract_t">Qi WX, Min DL, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 2013; 132:2967.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 30, 2024).</li><li><a class="nounderline abstract_t">Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol 2014; 78:748.</a></li><li><a class="nounderline abstract_t">Ghatalia P, Morgan CJ, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015; 94:228.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29:632.</a></li><li><a class="nounderline abstract_t">Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23:7685.</a></li><li><a class="nounderline abstract_t">Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14:552.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380:1103.</a></li><li><a class="nounderline abstract_t">van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.</a></li><li class="breakAll">FDA-approved manufacturer's labeling information available online at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7#section-6.5or= (Accessed on October 04, 2012).</li><li><a class="nounderline abstract_t">von Mehren M, Serrano C, Bauer S, et al. INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). Ann Oncol 2019; 30S: ESMO #LBA87.</a></li><li class="breakAll">Ripretinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf (Accessed on May 19, 2020).</li><li><a class="nounderline abstract_t">Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112:2500.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115.</a></li><li><a class="nounderline abstract_t">Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12:107.</a></li><li><a class="nounderline abstract_t">Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011; 29:3450.</a></li><li><a class="nounderline abstract_t">Witteles RM, Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned? J Clin Oncol 2012; 30:1916.</a></li><li><a class="nounderline abstract_t">Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.</a></li><li><a class="nounderline abstract_t">Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26:5204.</a></li><li><a class="nounderline abstract_t">Haas NB, Manola J, Ky B, et al. Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC). J Clin Oncol 2017; 30:(suppl; absr 4500).</a></li><li><a class="nounderline abstract_t">Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7:332.</a></li><li><a class="nounderline abstract_t">Hsieh PC, MacGillivray C, Gannon J, et al. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 114:637.</a></li><li><a class="nounderline abstract_t">Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 2010; 53:114.</a></li><li><a class="nounderline abstract_t">Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:97.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.</a></li><li><a class="nounderline abstract_t">Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013; 36:295.</a></li><li><a class="nounderline abstract_t">Hatem R, Bebawi E, Schampaert E. Potential Sunitinib-Induced Coronary Artery and Aortic Dissections. Can J Cardiol 2017; 33:830.e17.</a></li><li><a class="nounderline abstract_t">Oshima Y, Tanimoto T, Yuji K, Tojo A. Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database. Circulation 2017; 135:815.</a></li><li><a class="nounderline abstract_t">Bonnet C, Sibon I. Potential role of anti-VEGF targeted therapies in cervical artery dissection: A case report. Rev Neurol (Paris) 2015; 171:677.</a></li><li><a class="nounderline abstract_t">Formiga MN, Fanelli MF. Aortic dissection during antiangiogenic therapy with sunitinib. A case report. Sao Paulo Med J 2015; 133:275.</a></li><li><a class="nounderline abstract_t">Niwa N, Nishiyama T, Ozu C, et al. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta Oncol 2015; 54:561.</a></li><li><a class="nounderline abstract_t">Funahashi Y, Sassa N, Inada-Inoue M, et al. Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years. Aktuelle Urol 2014; 45:132.</a></li><li><a class="nounderline abstract_t">Edeline J, Laguerre B, Rolland Y, Patard JJ. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma. Ann Oncol 2010; 21:186.</a></li><li><a class="nounderline abstract_t">Aragon-Ching JB, Ning YM, Dahut WL. Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. Acta Oncol 2008; 47:1600.</a></li><li><a class="nounderline abstract_t">Brown DB. Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation. Semin Intervent Radiol 2011; 28:142.</a></li><li><a class="nounderline abstract_t">Mantia-Smaldone GM, Bagley LJ, Kasner SE, Chu CS. Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab. Gynecol Oncol Case Rep 2013; 5:37.</a></li><li><a class="nounderline abstract_t">Takada M, Yasui T, Oka T, et al. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. Int Heart J 2018; 59:1174.</a></li><li><a class="nounderline abstract_t">Guyon J, Gouverneur A, Maumus-Robert S, et al. Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms. JAMA Oncol 2021; 7:775.</a></li><li class="breakAll">https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00213 (Accessed on December 20, 2018).</li><li><a class="nounderline abstract_t">Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015; 112:296.</a></li><li><a class="nounderline abstract_t">Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25:3362.</a></li><li><a class="nounderline abstract_t">Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009; 15:7045.</a></li><li><a class="nounderline abstract_t">Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 2011; 67:751.</a></li><li class="breakAll">US FDA drug approval summary for vandetanib in medullary thyroid cancer available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf (Accessed on April 25, 2011).</li><li><a class="nounderline abstract_t">Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 2012; 7:e30353.</a></li><li class="breakAll">FDA-approved manufacturer's package insert for vandetanib available online at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525 (Accessed on January 25, 2013).</li><li><a class="nounderline abstract_t">Muluneh B, Richardson DR, Hicks C, et al. Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach. J Clin Oncol 2019; 37:2719.</a></li><li><a class="nounderline abstract_t">Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc 2017; 6.</a></li><li><a class="nounderline abstract_t">Richardson DR, Parish PC, Tan X, et al. Association of QTc Formula With the Clinical Management of Patients With Cancer. JAMA Oncol 2022; 8:1616.</a></li></ol></div><div id="topicVersionRevision">Topic 14250 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4938153" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tumor angiogenesis: therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285426" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22312105" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27022039" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30202791" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22124432" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24718482" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sorafenib cardiotoxicity increases mortality after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28824714" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23561917" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719546" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autocrine VEGF signaling is required for vascular homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23720580" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854721" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reversibility of capillary density after discontinuation of bevacizumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083403" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474115" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22651902" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12642354" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9530221" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778410" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Therapeutic angiogenesis and vasculogenesis for tissue regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078497" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Manipulating angiogenesis in medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956731" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446321" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Angiogenesis inhibitors and hypertension: an emerging issue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19150949" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Management of hypertension in angiogenesis inhibitor-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28104567" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29376753" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27602778" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20401474" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28950290" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18752081" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18221915" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23178953" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056247" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056247" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671254" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22949147" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25236375" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19773379" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172185" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Home blood-pressure monitoring in patients receiving sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351338" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25117820" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25617075" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vascular Endothelial Growth Factor A c.*237C&gt;T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21807768" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20085937" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824714" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19921473" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evaluation of hypertension as a marker of bevacizumab efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842611" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427348" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21527770" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547010" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492223" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19727565" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23485622" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321011" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901116" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19967539" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15161894" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prognostic importance of comorbidity in a hospital-based cancer registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21549588" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290365" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704059" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Thrombotic events in patients with cancer receiving antiangiogenesis agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202119" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11166270" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899768" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519900" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mechanisms of adverse effects of anti-VEGF therapy for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21273347" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21273347" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686822" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115602" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20,000 Patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20156114" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22921183" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22977191" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22977191" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22977191" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22977191" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017914" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422411" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422411" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245868" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245868" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351323" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215530" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sorafenib in advanced clear-cell renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383474" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494585" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15161690" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734456" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355900" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23317774" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23225494" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23225494" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24661224" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577572" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205755" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Congestive heart failure risk in patients with breast cancer treated with bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234530" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cardiotoxicity of cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681523" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23598172" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779531" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595799" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595799" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18386829" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215529" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227905" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810682" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22454419" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Underestimating cardiac toxicity in cancer trials: lessons learned?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650514" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Sorafenib in advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838713" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457301" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894033" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20728698" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Why do kinase inhibitors cause cardiotoxicity and what can be done about it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248973" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23620167" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461000" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Potential Sunitinib-Induced Coronary Artery and Aortic Dissections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28223329" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25912472" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Potential role of anti-VEGF targeted therapies in cervical artery dissection: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25351639" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Aortic dissection during antiangiogenic therapy with sunitinib. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25291078" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700069" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875754" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18607842" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22654250" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24371692" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30158382" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33734295" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33734295" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349964" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664484" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Molecularly targeted oncology therapeutics and prolongation of the QT interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903787" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20521052" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20521052" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22363427" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22363427" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31310577" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217664" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36136321" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Association of QTc Formula With the Clinical Management of Patients With Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
